Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT05329623
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
Phase 1
Completed
- Conditions
- or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT05328752
- Locations
- 🇺🇸
Jacksonville Ctr for Clin Rea Main Centre, Jacksonville, Florida, United States
🇳🇱Novartis Investigative Site, Groningen, Netherlands
🇺🇸Nature Coast Clinical Research LLC, Inverness, Florida, United States
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17743
- Registration Number
- NCT05320159
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase 3
Completed
- Conditions
- Hyperlipoproteinemia(a)
- Interventions
- Drug: Corresponding Placebo
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT05305664
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
Completed
- Conditions
- Retinopathy of Prematurity
- Interventions
- Other: Lucentis
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT05304949
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
Recruiting
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT05301907
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study
Completed
- Conditions
- PIK3CA-related Overgrowth Spectrum
- Interventions
- Other: Alpelisib
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05294289
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Post Marketing Surveillance on Piqray in Korea
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: Piqray
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 900
- Registration Number
- NCT05293470
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Recruiting
- Conditions
- Multiple Sclerosis
- Interventions
- Other: Ofatumumab
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT05285904
- Locations
- 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath